84 related articles for article (PubMed ID: 26859672)
21. Metabolism of the taxanes including nab-paclitaxel.
Joerger M
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):691-702. PubMed ID: 25394848
[TBL] [Abstract][Full Text] [Related]
22. Metaxalone-induced Immune Hemolytic Anemia.
Onyechi A; Ohemeng-Dapaah J; Patel R; Onyechi E; Oyenuga M; Sartaj S; Mehta M; Lacasse A; Anyadibe IE
J Community Hosp Intern Med Perspect; 2023; 13(5):86-89. PubMed ID: 37868679
[TBL] [Abstract][Full Text] [Related]
23. Case Report: Oral Cimetidine Administration Causes Drug-Induced Immune Hemolytic Anemia by Eliciting the Production of Cimetidine-Dependent Antibodies and Drug-Independent Non-specific Antibodies.
Wu Y; Wu Y; Ji Y; Liu Y; Wu D; Liang J; Guo G; Chen B
Front Med (Lausanne); 2021; 8():723167. PubMed ID: 34646843
[TBL] [Abstract][Full Text] [Related]
24. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
25. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel.
Foote M
Biotechnol Annu Rev; 2007; 13():345-57. PubMed ID: 17875482
[TBL] [Abstract][Full Text] [Related]
26. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
[TBL] [Abstract][Full Text] [Related]
27. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.
Wiedenmann N; Valdecanas D; Hunter N; Hyde S; Buchholz TA; Milas L; Mason KA
Clin Cancer Res; 2007 Mar; 13(6):1868-74. PubMed ID: 17363543
[TBL] [Abstract][Full Text] [Related]
28. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
Guarneri V; Dieci MV; Conte P
Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
[TBL] [Abstract][Full Text] [Related]
29. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.
Demeure MJ; Stephan E; Sinari S; Mount D; Gately S; Gonzales P; Hostetter G; Komorowski R; Kiefer J; Grant CS; Han H; Von Hoff DD; Bussey KJ
Ann Surg; 2012 Jan; 255(1):140-6. PubMed ID: 22156929
[TBL] [Abstract][Full Text] [Related]
30. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
Vishnu P; Roy V
Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
[TBL] [Abstract][Full Text] [Related]
31. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
Chirgwin J; Chua SL
Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
[TBL] [Abstract][Full Text] [Related]
32. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
33. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
Stinchcombe TE
Nanomedicine (Lond); 2007 Aug; 2(4):415-23. PubMed ID: 17716129
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
36. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Petrelli F; Borgonovo K; Barni S
Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
38. Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer.
Socinski MA; Govindan R; Spigel D
Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 18):1-16. PubMed ID: 23187688
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of supportive care for albumin-bound paclitaxel(nab-paclitaxel)in 20 patients with metastatic breast cancer].
Yamada C; Yonezawa M; Shimizu Y; Taga R; Kashihara H; Tsuji K; Murata T; Yoshino H
Gan To Kagaku Ryoho; 2014 Jan; 41(1):77-81. PubMed ID: 24423956
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
